BiotechTube
YGION Biomedical

YGION Biomedical

Vienna, Austria· Est.
ygion.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

YGION Biomedical is a private, pre-clinical stage biotech developing a novel class of individualized cancer vaccines. Its core technology, the YGNITE platform, integrates tumor genomics, bioinformatics, and a proprietary immune-modulating carrier (CARGONAUT) to synthesize patient-specific neoantigen vaccines designed to activate the immune system precisely against tumors. The company is well-capitalized following a €15 million Series A round in 2024 and a significant Austrian research grant, positioning it to advance its platform and pipeline toward clinical development in the competitive but high-potential field of personalized oncology.

Oncology

Technology Platform

The YGNITE platform integrates tumor genomics (NGS), proprietary bioinformatics for neoantigen selection, and a proprietary immune-modulating carrier system (CARGONAUT) to create 'plug-and-play' personalized peptide cancer vaccines. The CARGONAUT carrier is designed for targeted delivery and activation of antigen-presenting cells.

Opportunities

The validated success of other neoantigen vaccine platforms creates a receptive market for YGION's alternative 'plug-and-play' peptide approach.
Significant recent funding provides a multi-year runway to generate compelling proof-of-concept data and advance toward clinical trials, potentially attracting partnership interest.

Risk Factors

The company faces high scientific risk as its core CARGONAUT technology is unproven in humans.
It operates in an intensely competitive landscape dominated by well-capitalized players with advanced clinical programs.
The complex logistics and high costs of manufacturing personalized therapies present significant operational and commercial challenges.

Competitive Landscape

YGION competes in the crowded and rapidly advancing field of personalized cancer vaccines. Key competitors include BioNTech (mRNA platforms), Gritstone bio (viral vector & mRNA), and the Merck-Moderna partnership, all of which have candidates in later-stage clinical trials. YGION must differentiate on platform simplicity, potency, or manufacturing efficiency.

More companies in Oncology (General) →More companies in Austria →